Sophie Vandebroek Sells 1,464 Shares of IDEXX Laboratories (NASDAQ:IDXX) Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Director Sophie Vandebroek sold 1,464 shares of IDEXX Laboratories stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total value of $920,299.68. Following the sale, the director directly owned 648 shares of the company’s stock, valued at approximately $407,345.76. This represents a 69.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX traded down $4.17 during trading on Thursday, hitting $630.73. The stock had a trading volume of 307,461 shares, compared to its average volume of 506,699. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $769.98. The stock has a market capitalization of $50.36 billion, a price-to-earnings ratio of 48.26, a price-to-earnings-growth ratio of 3.81 and a beta of 1.67. The stock has a 50-day simple moving average of $680.64 and a two-hundred day simple moving average of $669.42.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing the consensus estimate of $2.93 by ($0.01). IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The business had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter last year, the company posted $2.53 EPS. IDEXX Laboratories’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, equities research analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Hedge Funds Weigh In On IDEXX Laboratories

Several hedge funds and other institutional investors have recently made changes to their positions in IDXX. Empowered Funds LLC raised its stake in IDEXX Laboratories by 6.6% in the 1st quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock valued at $646,000 after purchasing an additional 95 shares during the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of IDEXX Laboratories in the second quarter valued at about $265,000. Harbour Investments Inc. lifted its stake in shares of IDEXX Laboratories by 27.3% in the second quarter. Harbour Investments Inc. now owns 98 shares of the company’s stock worth $53,000 after buying an additional 21 shares in the last quarter. Mutual Advisors LLC acquired a new position in IDEXX Laboratories during the second quarter worth about $244,000. Finally, Nordea Investment Management AB grew its stake in IDEXX Laboratories by 4.7% during the 2nd quarter. Nordea Investment Management AB now owns 8,057 shares of the company’s stock valued at $4,298,000 after acquiring an additional 361 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on IDXX shares. JPMorgan Chase & Co. lifted their price target on IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Morgan Stanley lifted their target price on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Stifel Nicolaus set a $775.00 target price on shares of IDEXX Laboratories in a research note on Monday, November 3rd. UBS Group cut their price objective on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a report on Tuesday, February 3rd. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $830.00 price objective on shares of IDEXX Laboratories in a research report on Tuesday, November 4th. Seven analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $783.33.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.